BioSpace News Archive

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2022 financial results on Tuesday, November 1, 2022.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist Human Sample ID Kit to provide researchers with a solution to track samples throughout the lab workflow.

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative.

Xentria Inc. announced a $25 million growth equity funding round approved by its Board of Directors and the opening of a new corporate headquarters.

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS ® T Cell Therapy for Neuroblastoma.

Apollo Endosurgery, Inc. today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.

Cosmos Holdings announced the pricing of its “reasonable best efforts” public offering of 62,500,000 shares of common stock, Series A Warrants to purchase 62,500,000 shares of common stock and Series B Warrant to purchase 62,500,000 shares of common stock at a combined price of $0.12 per share and warrant for aggregate gross proceeds of $7.5 million, before deducting placement agent fees and other offering expenses.

Recce Pharmaceuticals Ltd is pleased to provide an update from its preclinical studies evaluating RECCE® 327 (R327) against the SARS-CoV-2 virus.

SynerFuse, Inc., an Eden Prairie, Minnesota-based medical device company, announced today that an independent Data Safety and Monitoring Board (DSMB) completed its pre-specified safety review of the first five implanted subjects in the company’s ongoing proof-of-concept study.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of Founder and CEO Alon Ben-Noon’s remarks at the Nasdaq Opening Bell Ceremony on October 13, 2022.